Deoxyfructo-serotonin: a new drug with anti-leprosy activity.
In the mouse foot pas, deoxyfructo-serotonin (DFS) shows a definite inhibitory effect on the multiplication of M. leprae in Dapsone-sensitive as well as Dapsone-resistant cases. In clinical trials, based on 7 cases treated with DFS for an average period of 6 months, the beneficial effects of DFS are observed after a few weeks of treatment in BB cases, and after a few months in LL cases. In addition to clear improvements in the appearance of the skin (regression and healing of nodules, almost complete disappearance of infiltration, etc) one observes in the majority of cases a rapid improvement in the bacteriological and morphological indexes, the latter falling to 0%. In the course of these studies, no single suggestion of intolerance was detected.
D000328:Adult; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007918:Leprosy / Q000188:drug therapy*; D008297:Male; D008302:Mali; D012701:Serotonin / Q000031:analogs & derivatives* / Q000627:therapeutic use
D012701:Serotonin; C018901:desoxyfructo-serotonin